Craig Jalbert
Chief Executive Officer at BETTER THERAPEUTICS, INC.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Naseem Amin | M | 62 | 9 years | |
| Patrick Flavin | M | - | 5 years | |
| Lori Murray | F | - | 6 years | |
| David Sinclair | M | - | 14 years | |
| Kathryn King | M | - | - | |
| Andrea Itano | M | - | 7 years | |
| Liz Melone | F | - | - | |
| Stuart Abel | M | - | 5 years | |
| Brett Belongia | M | - | - | |
| Julie Carretero | F | - | 4 years | |
| Leslie Wardwell-Scott | M | - | - | |
| Stephanie Duncanson | M | - | - | |
| Mark D. Plinio | M | 57 | 3 years | |
| Thiago Licias de Oliveira | M | - | 3 years | |
| Yixin He | M | - |
Mitralign, Inc.
 Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | - |
| Kent Grindstaff | M | - | 2 years | |
| Marissa Hanify | F | - | 4 years | |
| Chris German | M | - | - | |
| Diane Gomez-Thinnes | F | - | 2 years | |
| Emma Wiliams | F | - | - | |
| Bobae Kim | F | 42 | 2 years | |
| Dan Kirby | M | - | - | |
| Gina Balderas | F | - | - | |
| Lowey Keith | M | - |
Verdolino & Lowey PC
 Verdolino & Lowey PC Miscellaneous Commercial ServicesCommercial Services Verdolino & Lowey PC is a professional services firm that provides accounting, tax, and consulting services to individuals and businesses. The private company is based in Foxborough, MA. The company offers a range of services, including tax planning and preparation, financial statement preparation, bookkeeping, and business consulting. The company serves clients in various industries, including healthcare, real estate, construction, and retail. | - |
| Scott Oppenheim | M | - |
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | 7 years |
| Steven Paul | M | 73 |
Seaside Therapeutics LLC
 Seaside Therapeutics LLC Medical DistributorsDistribution Services Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA. | - |
| Duncan McHale | M | 57 | 6 years | |
| Peter Zarevics | M | - |
Seaside Therapeutics LLC
Seaside Therapeutics LLC Medical DistributorsDistribution Services Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA. | 16 years |
| Martinus Adrianus van Osch | M | - |
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | - |
| Dan Cole | M | 77 |
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | - |
| Marc Beer | M | 59 |
Seaside Therapeutics LLC
Seaside Therapeutics LLC Medical DistributorsDistribution Services Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA. | - |
| Yuval Binur | M | - |
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | - |
| Carrie J. L. Bates | F | - |
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | - |
| Mark W. Bodmer | M | 69 | 8 years | |
| Andres Camacho | M | - | - | |
| Tamyra A. Toole | F | - | 6 years | |
| Paul P. Wang | M | - |
Seaside Therapeutics LLC
Seaside Therapeutics LLC Medical DistributorsDistribution Services Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA. | - |
| Tim Noffke | M | - | 3 years | |
| Karen Dawes | F | 72 |
Seaside Therapeutics LLC
Seaside Therapeutics LLC Medical DistributorsDistribution Services Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA. | - |
| Jessica Cotrone | F | - | - | |
| Edwin L. Parsley | M | 63 | - | |
| Adam Groothuis | M | - |
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | 12 years |
| Christopher Lee | M | - |
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | 18 years |
| David R. Schleifer | M | - |
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | 8 years |
| Martin Dekker | M | 51 | 9 years | |
| Chun Zhang | M | - | 7 years | |
| James Jogerst | M | - | 3 years | |
| Aditya Puri | M | 53 |
Mitralign, Inc.
Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA. | - |
| Leslie Miller | F | 43 | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Theodore Ashburn | M | 57 | 5 years | |
| Andrew Kidd | M | 48 | 6 years | |
| Mitchell Finer | M | 65 | 8 years | |
| Frank Karbe | M | 56 | 2 years | |
| Jeffrey Biunno | M | 57 | 10 years | |
| Brian Shea | M | 36 | 2 years | |
| Pablo Cagnoni | M | 60 | 5 years | |
| William J. Schmidt | M | 69 |
Ibis Technology Corp.
 Ibis Technology Corp. SemiconductorsElectronic Technology Ibis Technology Corp. develops, manufactures and markets SIMOX-SOI implantation equipment for the worldwide semiconductor industry. SIMOX creates an insulating oxide barrier below the top surface of a silicon wafer through implantation and annealing. The company's proprietary oxygen implanters produce SIMOX-SOI wafers by implanting oxygen atoms just below the surface of a silicon wafer to create a very thin layer of silicon dioxide between the thin operating region of the transistor at the surface and the underlying silicon wafer itself. It was founded in October 1987. | 8 years |
| David Greenwood | M | 72 | 4 years | |
| Joseph Sarret | M | 56 | 2 years | |
| Alexander Nolte | M | 52 | - | |
| Albion Fitzgerald | M | 75 | 9 years | |
| Spencer Nam | M | 55 | 4 years | |
| Andrew Armanino | M | 59 | 3 years | |
| Patricia Randall | F | 72 |
MZT Holdings, Inc.
 MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | - |
| Mary Fenton | F | 60 | 4 years | |
| Richard Carmona | M | 74 | 7 years | |
| Geoffrey Parker | M | 59 | 3 years | |
| Elder Granger | M | 70 | 3 years | |
| Misha Petkevich | M | 75 | 4 years | |
| Risa Lavizzo-Mourey | M | 69 | 3 years | |
| Barbara Yanni | F | 69 | 2 years | |
| Ashish Khanna | M | 48 | 8 years | |
| Robert Hombach | M | 58 | 5 years | |
| Eric Rubin | M | 65 | 2 years | |
| Carol Nast | F | 78 | 2 years | |
| Joanne Yun | M | 53 | 2 years | |
| Keith D. Lowey | M | 61 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA.
Ibis Technology Corp.
Ibis Technology Corp. SemiconductorsElectronic Technology Ibis Technology Corp. develops, manufactures and markets SIMOX-SOI implantation equipment for the worldwide semiconductor industry. SIMOX creates an insulating oxide barrier below the top surface of a silicon wafer through implantation and annealing. The company's proprietary oxygen implanters produce SIMOX-SOI wafers by implanting oxygen atoms just below the surface of a silicon wafer to create a very thin layer of silicon dioxide between the thin operating region of the transistor at the surface and the underlying silicon wafer itself. It was founded in October 1987. | 4 years |
| David Perry | M | 56 | 9 years | |
| Martin J. Reid | M | 82 |
Ibis Technology Corp.
Ibis Technology Corp. SemiconductorsElectronic Technology Ibis Technology Corp. develops, manufactures and markets SIMOX-SOI implantation equipment for the worldwide semiconductor industry. SIMOX creates an insulating oxide barrier below the top surface of a silicon wafer through implantation and annealing. The company's proprietary oxygen implanters produce SIMOX-SOI wafers by implanting oxygen atoms just below the surface of a silicon wafer to create a very thin layer of silicon dioxide between the thin operating region of the transistor at the surface and the underlying silicon wafer itself. It was founded in October 1987. | 12 years |
| Mark Berman | M | 48 | 5 years | |
| Kristin Wynholds | F | 52 | 5 years | |
| Robert L. Gable | M | 93 |
Ibis Technology Corp.
Ibis Technology Corp. SemiconductorsElectronic Technology Ibis Technology Corp. develops, manufactures and markets SIMOX-SOI implantation equipment for the worldwide semiconductor industry. SIMOX creates an insulating oxide barrier below the top surface of a silicon wafer through implantation and annealing. The company's proprietary oxygen implanters produce SIMOX-SOI wafers by implanting oxygen atoms just below the surface of a silicon wafer to create a very thin layer of silicon dioxide between the thin operating region of the transistor at the surface and the underlying silicon wafer itself. It was founded in October 1987. | 12 years |
| Walter O. Fredericks | M | 84 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | - |
| Leslie B. Lewis | M | 83 |
Ibis Technology Corp.
Ibis Technology Corp. SemiconductorsElectronic Technology Ibis Technology Corp. develops, manufactures and markets SIMOX-SOI implantation equipment for the worldwide semiconductor industry. SIMOX creates an insulating oxide barrier below the top surface of a silicon wafer through implantation and annealing. The company's proprietary oxygen implanters produce SIMOX-SOI wafers by implanting oxygen atoms just below the surface of a silicon wafer to create a very thin layer of silicon dioxide between the thin operating region of the transistor at the surface and the underlying silicon wafer itself. It was founded in October 1987. | 11 years |
| Lamberto Raffaelli | M | 73 |
Ibis Technology Corp.
Ibis Technology Corp. SemiconductorsElectronic Technology Ibis Technology Corp. develops, manufactures and markets SIMOX-SOI implantation equipment for the worldwide semiconductor industry. SIMOX creates an insulating oxide barrier below the top surface of a silicon wafer through implantation and annealing. The company's proprietary oxygen implanters produce SIMOX-SOI wafers by implanting oxygen atoms just below the surface of a silicon wafer to create a very thin layer of silicon dioxide between the thin operating region of the transistor at the surface and the underlying silicon wafer itself. It was founded in October 1987. | 11 years |
| Richard Sandberg | M | 80 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | 9 years |
| Judith Kurland | F | 78 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | - |
| David L. Corbet | M | 70 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | 19 years |
| David Musket | M | 66 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | - |
| Robert Dolan | M | 72 |
Ibis Technology Corp.
Ibis Technology Corp. SemiconductorsElectronic Technology Ibis Technology Corp. develops, manufactures and markets SIMOX-SOI implantation equipment for the worldwide semiconductor industry. SIMOX creates an insulating oxide barrier below the top surface of a silicon wafer through implantation and annealing. The company's proprietary oxygen implanters produce SIMOX-SOI wafers by implanting oxygen atoms just below the surface of a silicon wafer to create a very thin layer of silicon dioxide between the thin operating region of the transistor at the surface and the underlying silicon wafer itself. It was founded in October 1987. | 21 years |
| Donald F. McGuinness | M | 91 |
Ibis Technology Corp.
Ibis Technology Corp. SemiconductorsElectronic Technology Ibis Technology Corp. develops, manufactures and markets SIMOX-SOI implantation equipment for the worldwide semiconductor industry. SIMOX creates an insulating oxide barrier below the top surface of a silicon wafer through implantation and annealing. The company's proprietary oxygen implanters produce SIMOX-SOI wafers by implanting oxygen atoms just below the surface of a silicon wafer to create a very thin layer of silicon dioxide between the thin operating region of the transistor at the surface and the underlying silicon wafer itself. It was founded in October 1987. | 13 years |
| Stephen D. Chubb | M | 80 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | - |
| Dimitri Antoniadis | M | 77 |
Ibis Technology Corp.
Ibis Technology Corp. SemiconductorsElectronic Technology Ibis Technology Corp. develops, manufactures and markets SIMOX-SOI implantation equipment for the worldwide semiconductor industry. SIMOX creates an insulating oxide barrier below the top surface of a silicon wafer through implantation and annealing. The company's proprietary oxygen implanters produce SIMOX-SOI wafers by implanting oxygen atoms just below the surface of a silicon wafer to create a very thin layer of silicon dioxide between the thin operating region of the transistor at the surface and the underlying silicon wafer itself. It was founded in October 1987. | 13 years |
| Robert Rosenthal | M | 67 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | - |
| C. William Zadel | M | 80 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | - |
| Bruce Lehman | M | 74 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | - |
| Jonathan M. Niloff | M | 70 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | - |
| T. Stephen Thompson | M | 76 |
MZT Holdings, Inc.
MZT Holdings, Inc. Medical SpecialtiesHealth Technology MZT Holdings, Inc. principal activity is to develop, manufacture, market, distribute and licensing of cancer diagnostic technologies and products. The products are based on proprietary nuclear matrix protein technology. The company has developed minimally invasive cancer diagnostic tests for bladder and colon cancer, cervical cancer, breast cancer and prostrate cancer, using proprietary technology and expertise. It was founded in 1987 and is headquartered Foxborough, MA. | 18 years |
| Stephanie Tozzo | M | 62 | 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Craig Jalbert
- Personal Network